Announcements
- Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
- Hofseth Biocare ASA: Annual General Meeting completed
- Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
- Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
- Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING
- Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION
- Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN
- Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT
- Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity
- Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED
More ▼
Key statistics
As of last trade Hofseth Biocare ASA (HBCo:STO) traded at 2.06, 2.49% above its 52-week low of 2.01, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.07 |
---|---|
High | 2.07 |
Low | 2.03 |
Bid | 2.09 |
Offer | 2.17 |
Previous close | 2.06 |
Average volume | 41.42k |
---|---|
Shares outstanding | 395.08m |
Free float | 165.07m |
P/E (TTM) | -- |
Market cap | 829.67m NOK |
EPS (TTM) | -0.2449 NOK |
Data delayed at least 15 minutes, as of May 22 2024 17:00 BST.
More ▼